NUVL Insider Trading

Insider Ownership Percentage: 12.52%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $233,053,197.08

Nuvalent Insider Trading History Chart

This chart shows the insider buying and selling history at Nuvalent by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$200M-$100M$0$100M$200MTotal Insider BuyingTotal Insider Selling

Nuvalent Share Price & Price History

Current Price: $66.29
Price Change: Price Increase of +4.3 (6.94%)
As of 04/11/2025 05:00 PM ET

This chart shows the closing price history over time for NUVL up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$66.29Closing price on 04/11/25:

SEC Filings (Institutional Ownership Changes) for Nuvalent (NASDAQ:NUVL)

97.26% of Nuvalent stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at NUVL by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$822kbought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$400M-$200M$0$200M$400MTotal InflowsTotal Outflows
Nuvalent logo
Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Read More on Nuvalent

Today's Range

Now: $66.29
Low: $60.25
High: $66.53

50 Day Range

MA: $74.24
Low: $59.32
High: $88.96

52 Week Range

Now: $66.29
Low: $55.54
High: $113.51

Volume

584,193 shs

Average Volume

476,387 shs

Market Capitalization

$4.75 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.43

Who are the company insiders with the largest holdings of Nuvalent?

Nuvalent's top insider shareholders include:
  1. James E Flynn (Director)
  2. Andrew A F Hack (Director)
  3. Matthew Shair (Director)
  4. James Richard Porter (CEO)
  5. Henry E Pelish (Insider)
  6. Alexandra Balcom (CFO)
  7. Darlene Noci (Insider)
  8. Deborah Ann Miller (Insider)
  9. Christopher Durant Turner (Insider)
  10. Emily Conley (Director)
  11. Anna Protopapas (Director)
Learn More about top insider investors at Nuvalent.

Who are the major institutional investors of Nuvalent?

Nuvalent's top institutional shareholders include:
  1. Rhumbline Advisers — 0.07%
  2. GAMMA Investing LLC — 0.01%
Learn More about top institutional investors of Nuvalent stock.

Which institutional investors are buying Nuvalent stock?

In the last quarter, NUVL stock was purchased by institutional investors including:
  1. GAMMA Investing LLC
  2. Rhumbline Advisers